Development of PI3Kγ selective inhibitors: the strategies and application

被引:3
|
作者
Gu, Dong-Yan [1 ]
Zhang, Meng-Meng [2 ]
Li, Jia [2 ]
Zhou, Yu-Bo [2 ]
Sheng, Rong [1 ]
机构
[1] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Peoples R China
[2] Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, State Key Lab Drug Res, Shanghai 201203, Peoples R China
基金
中国国家自然科学基金;
关键词
PI3K; PI3K gamma inhibitors; isoform selectivity; drug development; rational drug design; PI3K INHIBITORS; SOLID TUMORS; INFLAMMATION; DISCOVERY; PI3K-DELTA; TARGETS; THERAPY; LESSONS; PATHWAY;
D O I
10.1038/s41401-023-01166-8
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The gamma isoform of Class I PI3Ks (PI3K gamma) is primarily found in leukocytes and is essential for the function of myeloid cells, as it regulates the migration, differentiation, and activation of myeloid-lineage immune cells. Thus, PI3K gamma has been identified as a promising drug target for the treatment of inflammation, autoimmune disease, and immuno-oncology. Due to the high incidence of serious adverse events (AEs) associated with PI3K inhibitors, in the development of PI3K gamma inhibitors, isoform selectivity was deemed crucial. In this review, an overview of the development of PI3K gamma selective inhibitors in the past years is provided. The isoform selectivity of related drugs was achieved by different strategies, including inducing a specificity pocket by a propeller-shape structure, targeting steric differences in the solvent channel, and modulating the conformation of the Asp-Phe-Gly DFG motif, which have been demonstrated feasible by several successful cases. The insights in this manuscript may provide a potential direction for rational drug design and accelerate the discovery of PI3K gamma selective inhibitors.
引用
收藏
页码:238 / 247
页数:10
相关论文
共 50 条
  • [31] Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors
    Barlaam, Bernard
    Cosulich, Sabina
    Fitzek, Martina
    Germain, Herve
    Green, Stephen
    Hanson, Lyndsey L.
    Harris, Craig S.
    Hancox, Urs
    Hudson, Kevin
    Lambert-van der Brempt, Christine
    Lamorlette, Maryannick
    Magnien, Francoise
    Ouvry, Gilles
    Page, Ken
    Ruston, Linette
    Ward, Lara
    Delouvrie, Benedicte
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (13) : 3030 - 3035
  • [32] Highly Selective Inhibitors Of Pi3kγ For The Oral Treatment Of COPD
    Karabelas, K.
    Arlbrandt, S.
    Bold, P.
    Butcher, A.
    Carlsson, J. F.
    Cygan, P.
    Ehnebom, J.
    Goodyear, C.
    MacLellan, L.
    Nordberg, M.
    Lindmark, H.
    Mogemark, M.
    Pehrson, R.
    Perry, M.
    Blomqvist, S. R.
    Stern, A.
    Thomas, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [33] Selective PI3Kδ Inhibitors as Anti-NASH Agents
    Vakkalanka, Swaroop
    Muthuppalaniappan, Meyyappan
    Babu, G.
    Varanasi, Kanthikiran
    Routhu, Kasiviswanath
    Nyayapathy, Seeta
    Veeraraghavan, Sridhar
    Viswanadha, Srikant
    Nagaratham, Dhanapalan
    DIABETES, 2012, 61 : A84 - A84
  • [34] Development of PI3K inhibitors in breast cancer.
    Ma, Cynthia X.
    MOLECULAR CANCER RESEARCH, 2020, 18 (10) : 22 - 23
  • [35] Research advances on selective phosphatidylinositol 3 kinase δ (PI3Kδ) inhibitors
    Sun, Jiajia
    Feng, Yifan
    Huang, Yuan
    Zhang, San-Qi
    Xin, Minhang
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 30 (19)
  • [36] Strategies to overcome resistance to PI3Kalpha-selective inhibitors mediated by acquired alterations in the PI3K/AKT pathway
    de la Cruz, Ferran Fece
    Varkaris, Andreas
    Martin, Elizabeth E.
    Norden, Bryanna L.
    Chevalier, Nicholas
    Kehlmann, Allison M.
    Leshchiner, Ignaty
    Barnes, Haley
    Ehnstrom, Sara
    Patel, Parasvi
    Kim, Janice S.
    Ellis, Haley
    Sanidas, Ioannis
    Lau, Kayao T.
    Bardia, Aditya
    Spring, Laura M.
    Isakoff, Steven J.
    Lennerz, Jochen K.
    Getz, Gad
    Corcoran, Ryan B.
    Juric, Dejan
    CANCER RESEARCH, 2024, 84 (07)
  • [37] Imidazopyridazine Inhibitors of PI3Kβ
    Rosse, Gerard
    ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (12): : 1012 - 1013
  • [38] Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
    Rewcastle, Gordon W.
    Kolekar, Sharada
    Buchanan, Christina M.
    Gamage, Swarna A.
    Giddens, Anna C.
    Tsang, Kit Y.
    Kendall, Jackie D.
    Singh, Ripudaman
    Lee, Woo-Jeong
    Smith, Greg C.
    Han, Weiping
    Matthews, David J.
    Denny, William A.
    Shepherd, Peter R.
    Jamieson, Stephen M. F.
    ONCOTARGET, 2017, 8 (29) : 47725 - 47740
  • [39] Selective PI3K and dual PI3K/mTOR inhibitors enhance the efficacy of endocrine therapies in breast cancer models
    Friedman, L.
    Ross, L. B.
    Wallin, J.
    Guan, J.
    Prior, W. W.
    Wu, E.
    Nannini, M.
    Sampath, D.
    CANCER RESEARCH, 2012, 72
  • [40] Targeting phosphatidylinositol 3-kinase gamma (PI3Kγ): Discovery and development of its selective inhibitors
    Zhu, Jingyu
    Li, Kan
    Yu, Li
    Chen, Yun
    Cai, Yanfei
    Jin, Jian
    Hou, Tingjun
    MEDICINAL RESEARCH REVIEWS, 2021, 41 (03) : 1599 - 1621